CryoPort (NASDAQ:CYRX) Stock Price Crosses Above 200 Day Moving Average - What's Next?

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.68 and traded as high as $7.55. CryoPort shares last traded at $7.44, with a volume of 427,632 shares.

Analyst Ratings Changes

CYRX has been the topic of a number of research analyst reports. Roth Mkm reiterated a "buy" rating and issued a $15.00 target price on shares of CryoPort in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of CryoPort in a research note on Thursday, May 8th. UBS Group increased their target price on shares of CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Morgan Stanley reduced their price target on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, Guggenheim reissued a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a research report on Wednesday, April 16th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, CryoPort presently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

CryoPort Trading Up 2.7%

The firm has a fifty day moving average of $6.54 and a 200 day moving average of $6.67. The firm has a market capitalization of $383.07 million, a PE ratio of -3.26 and a beta of 1.89. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. Equities research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Activity

In related news, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24. Following the transaction, the chief executive officer owned 912,419 shares in the company, valued at approximately $6,213,573.39. The trade was a 14.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert J. Hariri sold 12,500 shares of CryoPort stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total value of $76,250.00. Following the sale, the director owned 8,061 shares in the company, valued at $49,172.10. This represents a 60.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 449,719 shares of company stock worth $3,042,327. 10.00% of the stock is owned by corporate insiders.

Institutional Trading of CryoPort

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. grew its holdings in CryoPort by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after acquiring an additional 1,512 shares in the last quarter. Rhumbline Advisers raised its position in shares of CryoPort by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after purchasing an additional 1,764 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in shares of CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares during the period. Sierra Summit Advisors LLC lifted its holdings in shares of CryoPort by 5.0% in the 1st quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company's stock worth $274,000 after purchasing an additional 2,150 shares during the last quarter. Finally, Nebula Research & Development LLC boosted its position in CryoPort by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock valued at $97,000 after purchasing an additional 2,207 shares during the period. Institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.